Literature DB >> 24861129

Treating epilepsy in the setting of medical comorbidities.

Nivedita U Jerath1, Dronacharya Lamichhane, Madhu Jasti, Vinusha Yarlagadda, Eduardo Zilli, Yara Nazzal, Mark Granner.   

Abstract

OPINION STATEMENT: Treatment of epilepsy in patients with medical comorbidities can be challenging. Comorbidities can affect medical management and quality of life. In this review, we discuss treatment options in patients with epilepsy and medical comorbidities. In our opinion, the best way to manage patients with medical comorbidities and epilepsy is to accurately recognize and diagnose medical comorbidities, and to have adequate knowledge and familiarity with antiepileptic drug (AED) metabolism, dosing, side effects, and drug interactions. We believe the trend should move toward using the newer generation of AEDs given their generally reduced rate of adverse effects and interactions. The primary goal of therapy is seizure freedom without side effects.

Entities:  

Year:  2014        PMID: 24861129     DOI: 10.1007/s11940-014-0298-1

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.598


  64 in total

1.  The Association Between Antiepileptic Drugs and Bone Disease.

Authors:  Alison M. Pack
Journal:  Epilepsy Curr       Date:  2003-05       Impact factor: 7.500

Review 2.  Alternative approaches to epilepsy treatment.

Authors:  Caitlin McElroy-Cox
Journal:  Curr Neurol Neurosci Rep       Date:  2009-07       Impact factor: 5.081

3.  Zonisamide for weight reduction in obese adults: a 1-year randomized controlled trial.

Authors:  Kishore M Gadde; Mariko F Kopping; H Ryan Wagner; Gretchen M Yonish; David B Allison; George A Bray
Journal:  Arch Intern Med       Date:  2012-11-12

4.  Characterization of insulin secretion in Valproate-treated patients with epilepsy.

Authors:  Virpi Pylvänen; Arto Pakarinen; Mikael Knip; Jouko Isojärvi
Journal:  Epilepsia       Date:  2006-09       Impact factor: 5.864

Review 5.  Drug dosing in chronic kidney disease.

Authors:  Steven Gabardi; Stuart Abramson
Journal:  Med Clin North Am       Date:  2005-05       Impact factor: 5.456

Review 6.  Importance of weight management in type 2 diabetes: review with meta-analysis of clinical studies.

Authors:  James W Anderson; Cyril W C Kendall; David J A Jenkins
Journal:  J Am Coll Nutr       Date:  2003-10       Impact factor: 3.169

7.  Pharmacokinetics of lamotrigine in patients with renal impairment: influence of haemodialysis.

Authors:  J P Fillastre; A M Taburet; A Fialaire; I Etienne; R Bidault; E Singlas
Journal:  Drugs Exp Clin Res       Date:  1993

8.  A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis.

Authors:  Frederick G Freitag; S D Collins; H A Carlson; J Goldstein; J Saper; S Silberstein; N Mathew; P K Winner; R Deaton; K Sommerville
Journal:  Neurology       Date:  2002-06-11       Impact factor: 9.910

9.  Obstructive sleep apnea in a clinical series of adult epilepsy patients: frequency and features of the comorbidity.

Authors:  Raffaele Manni; Michele Terzaghi; Carla Arbasino; Ivana Sartori; Carlo Andrea Galimberti; Amelia Tartara
Journal:  Epilepsia       Date:  2003-06       Impact factor: 5.864

10.  Two-year seizure reduction in adults with medically intractable partial onset epilepsy treated with responsive neurostimulation: final results of the RNS System Pivotal trial.

Authors:  Christianne N Heck; David King-Stephens; Andrew D Massey; Dileep R Nair; Barbara C Jobst; Gregory L Barkley; Vicenta Salanova; Andrew J Cole; Michael C Smith; Ryder P Gwinn; Christopher Skidmore; Paul C Van Ness; Gregory K Bergey; Yong D Park; Ian Miller; Eric Geller; Paul A Rutecki; Richard Zimmerman; David C Spencer; Alica Goldman; Jonathan C Edwards; James W Leiphart; Robert E Wharen; James Fessler; Nathan B Fountain; Gregory A Worrell; Robert E Gross; Stephan Eisenschenk; Robert B Duckrow; Lawrence J Hirsch; Carl Bazil; Cormac A O'Donovan; Felice T Sun; Tracy A Courtney; Cairn G Seale; Martha J Morrell
Journal:  Epilepsia       Date:  2014-02-22       Impact factor: 5.864

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.